PPCB
HEALTHCAREPropanc Biopharma Inc
$0.10-0.00 (-1.66%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PPCB Today?
No stock-specific AI insight has been generated for PPCB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.09$10.81
$0.10
Fundamentals
Market Cap$2M
P/E Ratio0.0
EPS$52.11
Dividend Yield—
Dividend / Share—
ROE-18.1%
Profit Margin—
Debt / Equity—
Trading
Volume294K
Avg Volume (10D)—
Shares Outstanding21.9M
PPCB News
19 articles- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, SpainYahoo Finance·Mar 24, 2026
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme TherapyYahoo Finance·Mar 12, 2026
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human StudyYahoo Finance·Mar 10, 2026
- Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic ModelsYahoo Finance·Mar 3, 2026
- Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 ResultsYahoo Finance·Feb 18, 2026
- Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer MarketYahoo Finance·Feb 5, 2026
- Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme FormulationsYahoo Finance·Jan 27, 2026
- Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP AustraliaYahoo Finance·Jan 20, 2026
- Propanc Biopharma Explains How PRP Could Impact Pancreatic CancerYahoo Finance·Jan 15, 2026
- Propanc Biopharma Provides Shareholder UpdateYahoo Finance·Jan 13, 2026
- Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed JournalYahoo Finance·Dec 22, 2025
- Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos LabsYahoo Finance·Dec 4, 2025
- Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and FibrosisYahoo Finance·Dec 1, 2025
- Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 ResultsYahoo Finance·Nov 17, 2025
- Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark OfficeYahoo Finance·Sep 17, 2025
- D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 UplistingYahoo Finance·Aug 28, 2025
- Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQYahoo Finance·Aug 19, 2025
- BC-Most Active StocksYahoo Finance·Aug 18, 2025
- Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public OfferingYahoo Finance·Aug 15, 2025
All 19 articles loaded
Price Data
Open$0.00
Previous Close$0.10
Day High$0.00
Day Low$0.00
52 Week High$10.81
52 Week Low$0.09
52-Week Range
$0.09$10.81
$0.10
Fundamentals
Market Cap$2M
P/E Ratio0.0
EPS$52.11
Dividend Yield—
Dividend / Share—
ROE-18.1%
Profit Margin—
Debt / Equity—
Trading
Volume294K
Avg Volume (10D)—
Shares Outstanding21.9M
About Propanc Biopharma Inc
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—